What is DermTech?
DermTech, Inc. operates at the forefront of the molecular diagnostics sector, specializing in the development and commercialization of non-invasive genomic tests. The company's core technology focuses on the early detection and management of melanoma, a critical area where traditional biopsy methods often present limitations. By utilizing adhesive patch technology to collect skin samples for genomic analysis, DermTech provides clinicians with actionable insights that improve diagnostic accuracy and patient outcomes. This market position is bolstered by a robust intellectual property portfolio and a commitment to evidence-based medicine, making the firm a key innovator in the rapidly evolving landscape of dermatological diagnostics.
How much funding has DermTech raised?
DermTech has raised a total of $87.4M across 4 funding rounds:
Other Financing Round
$10M
Other Financing Round
$2.4M
Series C
$10M
Share Placement
$65M
Other Financing Round (2007): $10M with participation from Gary Jacobs and Gene Salkind
Other Financing Round (2015): $2.4M led by Undisclosed
Series C (2017): $10M supported by RTW Investments
Share Placement (2020): $65M featuring Undisclosed
Key Investors in DermTech
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
Gary Jacobs
An early-stage investor and private backer with a focus on supporting innovative healthcare and diagnostic technology ventures.
Gene Salkind
A private investor providing strategic capital to support the development of novel medical technologies and diagnostic platforms.
What's next for DermTech?
Looking ahead, the strategic deployment of the $65M investment will likely focus on expanding the clinical utility of DermTech's genomic testing suite and scaling its commercial operations. As the company transitions into a more mature phase of enterprise-level growth, the focus will shift toward increasing market penetration and securing broader insurance coverage for its diagnostic services. Furthermore, the firm is expected to continue its research and development efforts to explore additional applications for its non-invasive sampling technology, potentially extending its diagnostic capabilities beyond melanoma to other skin conditions. This strategic roadmap aims to solidify DermTech's leadership in the molecular diagnostics market while driving long-term value for stakeholders and improving the standard of care for patients globally.
See full DermTech company page
